October 31, 2018 / 1:34 AM / in 15 days

China's Innovent rises 2.3 pct in Hong Kong debut

HONG KONG, Oct 31 (Reuters) - Innovent Biologics climbed 2.3 percent in a Hong Kong debut closely watched as a test of investor appetite for Chinese biotechs after three rivals saw their shares slide post-listing.

The Chinese biotech - backed by mutual fund giant Fidelity and Singapore state investor Temasek Holdings - was trading at HK$14.3 on Wednesday morning, above its IPO price of HK$13.98.

It is the fourth listing under new rules in Hong Kong aimed at wooing early-stage drug developers.

Reporting by Julia Fioretti and Kane Wu; Editing by Edwina Gibbs

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below